Therapy Areas: Vaccines
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
31 March 2026 - Delonix Bioworks, a clinical-stage biotechnology company developing genetically engineered bacterial vaccines, announced on Monday the initiation of first-in-human (FIH) dosing in a Ph...
GC Biopharma secures first Latin American approval for BARYCELA Inj.
...
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
25 March 2026 - Commercial-stage biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) on Tuesday reported additional positive data from a Phase I clinical trial in the United States evalua...
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
23 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) and French vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Monday reported positive topline results from the Phase 3...
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
19 March 2026 - Swedish life science tools company Mabtech announced on Wednesday a strategic collaboration with Sai Life Sciences, a global Contract Research Organisation (CRO).Under the agreement, S...
Elaris FlexCo signs global licence agreement with Valneva
19 March 2026 - Elaris FlexCo, an Austrian biotechnology company developing vaccines against serious bacterial infections, announced on Wednesday that it has signed a licensing agreement with French v...